周大鹏 - 同济大学

个人简介

发现了肺癌特异表达的MUC1糖肽抗原并研发特异性抗体，转让给美国 BioLegend公司， Sony Biotechnology 公司，和加拿大Stem Cell Technologies 公司。发现了糖脂类抗原递呈通路的关键辅助蛋白Saposins, 发现了自然杀伤T细胞的自身抗原isoglobotriaosylceramide在Science，Nature, JCI, PNAS, J Proteome Research, JBC，Glycobiology 等杂志上发表SCI论文65篇，被引用3790次，H-index 27, 获得过瑞士苏黎世大学优秀医学博士论文奖，美国纽约癌症基金会Irvington 奖，德州大学安德森癌症中心Robert M Chamberlain优秀导师奖提名。工作被美国化学会糖化学部（ACS CARB）， Faculty of 1000， The Scientist 等科学媒体报道。主要任职国家高层次青年人才中国生物化学和分子生物学学会糖复合物分会委员上海市医学会医学病毒学学会委员中国生物化学和分子生物学学会临床医学分会委员

研究领域

糖复合物在疾病发生发展中的免疫机制研究糖复合物作为疾病诊断和治疗靶点的发现和转化医学研究抗体和CAR-T药物的研发

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Tong, J.; Zhu, C.; Lai, H.; Feng, C.; Zhou, D. Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19. Vaccines 2021, 9, 296. (唯一通讯,影响因子 4.4) Zhou D, Xia C, Wang PG, Li Z, Zhang W, Ni G, Cheng J. Genetic Studies of Natural Glycosphingolipid Ligands for NKT Cells. Methods Mol Biol. 2021;2388:13-25. (共同通讯) Zhou D, Tian X, Qi R, Peng C, Zhang W. Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: implications for vaccination and antibody therapeutics. Glycobiology. 2020 Jun 10:cwaa052. Pan D, Tang Y, Tong J, Xie C, Chen J, Feng C, Tong J, Hwu P, Huang W, Zhou D* An antibody drug conjugate targeting a GSTA glycosite-signature epitope of mucin1 expressed by non-small cell lung cancer (唯一通讯,影响因子 4.5) . 2020 Cancer Med. 2020 Oct 20. Pan D, Chen J, Feng C, Wu W, Wang Y, Tong J, Zhou D*. Preferential Localization of MUC1 Glycoprotein in Exosomes Secreted by Non-Small Cell Lung Carcinoma Cells.Int. J. Mol. Sci. 2019, 20(2), 323 （唯一通讯, 影响因子 3.7） Zhou D*, Xiao K, Tian Z*. Separation and detection of minimal length isomeric glycopeptide neoantigen epitopes centering GSTA region of MUC1 by LC-MS. (共同通讯, 影响因子2.2) Rapid Communications in Mass Spectrometry, 2019 Oct 28. doi: 10.1002/rcm.8622. [Epub ahead of print] Pan D, Zhou D*, Cai W, Wu W, Tan WL, Caicun Zhou1, Yanyan Lou2* Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma (共同通讯, 影响因子2.2) BMC Immunol. 2019 Nov 13;20(1):43. Cai W, Zhou D*, Wu W, Tan WL, Wang J, Zhou C, Lou Y*. MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design. 2018 BMC Genomics. 2018 Aug 3;19(1):582. doi: 10.1186/s12864-018-4958-5.（共同通讯, 影响因子 3.7） Zhou D, Xu L, Huang W, Tonn T. Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy. Molecules. 2018 May 31;23(6).（共同通讯, 影响因子 3.0） Ma Q*, DeLyria ES*, Zhou D*, Wen X, Lu W, Thapa P, Liu C, Li D, Bassett RL Jr., Overwijk WW, Hwu P, Li C. Synthetic poly(L-glutamic acid)-conjugated CpG exhibits antitumor efficacy with increased retention in tumor and draining lymph nodes after intratumoral injection in a mouse model of melanoma. J. Immunotherapy. 2017 Jan;40(1):11-20 Qu J, Yu H, Li F, Zhang C, Trad A, Brooks C, Zhang B, Gong T, Guo Z, Li Y, Ragupathi G, Lou Y, Hwu P, Huang W, Zhou D. Molecular basis of antibody binding to mucin glycopeptides in lung cancer. Int J Oncol. 2016 Feb;48(2):587-94.